Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Arch Soc Esp Oftalmol (Engl Ed) ; 97(2): 89-99, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35152954

RESUMEN

Orbital inflammatory disease (OID), commonly known as orbital pseudotumour, is an inflammatory disease of unknown cause. It has different forms of presentation and different degrees of severity. Its variable nature is the main cause for this disease to be misdiagnosed and misclassified. The prognosis of OID depends on the tissues affected and the histology. OID usually responds favourably to systemic steroid treatment. However, empiric steroids may mask other underlying diseases that respond well to this treatment as well, namely, IgG4-related disease or lymphoproliferative disorders. This fact has led to controversy among various authors as some recommend performing a biopsy in most of the cases, whereas others defend that this procedure should only be performed if the patient has not responded to empiric steroid treatment. Although steroids have been the mainstream treatment of OID, the side effects, relapse rates and lack of response in some cases have resulted in them being replaced by immunosuppressive and immunomodulator therapies that currently stand as a key steroid-sparing treatment option, in addition to radiotherapy and surgery. The aim of this review is to update the evidence on the diagnosis and treatment of OID.


Asunto(s)
Enfermedad Relacionada con Inmunoglobulina G4 , Enfermedades Orbitales , Seudotumor Orbitario , Biopsia , Humanos , Inmunosupresores/uso terapéutico , Seudotumor Orbitario/diagnóstico , Seudotumor Orbitario/tratamiento farmacológico
3.
J Fr Ophtalmol ; 44(7): 1052-1058, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34148699

RESUMEN

PURPOSE: Intraocular lens (IOL) calculation and biometry have evolved significantly in recent decades. However, present outcomes are still suboptimal. Our objective is to summarize the results reported in the literature with regard to a new variable, the value of the relationship between anterior and posterior corneal curvature in the biometric calculation of IOL power. METHODS: We have created a narrative revision of the existing evidence regarding the posterior to anterior corneal curvature ratio in IOL calculation. RESULTS: The corneal posterior/anterior ratio (P/A ratio), also called Gullstrand ratio, has a standard deviation of 2.4% in normal people, hence causing a possible IOL power miscalculation error of up to 0.75 diopters (D). This error is magnified in pathological corneas or in those with previous refractive surgery. Including the P/A ratio in the IOL formula reduces errors in the calculation of IOL power. CONCLUSIONS: Measurement of the posterior corneal surface should be recommended prior to IOL calculation, given the demonstrated results regarding the P/A ratio for IOL power calculation. Regarding toric IOL calculation, we suggest incorporation of all internal astigmatic vectors, for instance, posterior corneal surface, IOL tilt induced toricity, and retinal astigmatism. All of these factors may improve surgical outcomes.


Asunto(s)
Astigmatismo , Lentes Intraoculares , Facoemulsificación , Astigmatismo/cirugía , Biometría , Córnea , Topografía de la Córnea , Humanos , Implantación de Lentes Intraoculares , Óptica y Fotónica , Refracción Ocular , Estudios Retrospectivos
8.
Arch Soc Esp Oftalmol (Engl Ed) ; 96(1): 45-47, 2021 Jan.
Artículo en Inglés, Español | MEDLINE | ID: mdl-32861528

RESUMEN

Haberland syndrome or encephalocutaneous lipomatosis is a very uncommon syndrome that is characterised by changes in the skin, eye, and central nervous system. It was first described in 1970 by Haberland and Perou, with about 60 cases having been reported since then. A case is reported of a 14-week-old male diagnosed with Haberland syndrome with bilateral ocular involvement in the form of palpebral coloboma and choristomas.

10.
J Fr Ophtalmol ; 43(8): 727-730, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32620415

RESUMEN

We report a case of a patient treated with tamoxifen 20mg daily as hormone therapy for breast cancer. On regular ophthalmological follow-up, tamoxifen maculopathy was detected on SD-OCT (Spectral Domain Optic Coherence Tomography, Carl Zeiss Meditec®), so the medication was discontinued. Despite discontinuation of the medication, the maculopathy progressed over time. We have been following our patient for seven years. Tamoxifen may produce a toxic maculopathy which may progress despite discontinuation of the medication. We consider our case interesting, given the lengthy follow-up of the patient with sequential SD-OCT images. To the best of our knowledge, our case represents the longest follow-up period for a patient with tamoxifen maculopathy. Moreover, we would like to stress the importance of screening in asymptomatic patients on this medication, in order to detect early pathological signs.


Asunto(s)
Monitoreo Fisiológico , Enfermedades de la Retina/inducido químicamente , Enfermedades de la Retina/diagnóstico , Tamoxifeno/efectos adversos , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Femenino , Angiografía con Fluoresceína , Estudios de Seguimiento , Humanos , Mácula Lútea/efectos de los fármacos , Mácula Lútea/patología , Degeneración Macular/inducido químicamente , Degeneración Macular/diagnóstico , Degeneración Macular/patología , Monitoreo Fisiológico/métodos , Enfermedades de la Retina/patología , Tamoxifeno/administración & dosificación , Tomografía de Coherencia Óptica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...